Suppr超能文献

意大利植入式心脏复律除颤器注册研究。2001 - 2003年全国活动调查。

The Italian Implantable Cardioverter-Defibrillator Registry. A survey of the national activity during the years 2001-2003.

作者信息

Proclemer Alessandro, Ghidina Marco, Cicuttini Gloria, Gregori Dario, Fioretti Paolo M

机构信息

Division of Cardiology, S. Maria della Misericordia Hospital, Udine, Italy.

出版信息

Ital Heart J. 2005 Mar;6(3):272-80.

Abstract

BACKGROUND

In recent years several trials demonstrated the efficacy of implantable cardioverter-defibrillator (ICD) therapy for sudden cardiac death prevention and total mortality reduction in particular high-risk groups of patients. The aim of this review was to report the main epidemiological data and the most important clinical characteristics of patients enrolled in the Italian ICD Registry in the years 2001-2003.

METHODS

The Italian ICD Registry--official member of the Italian Association of Arrhythmology and Cardiac Pacing (AIAC)--collects 85% of the data concerning the national ICD implantation activity, based on the European Implantable Defibrillator form (EURID). Data are validated for quality of information and uniqueness at the moment of data entry and in successive steps at the time of the annual analysis.

RESULTS

The number of ICDs implanted in Italy has been continuing to increase during the last years according to the general trend in European and non-European countries: 2400 in the year 2001, 3934 in the year 2002, and 5318 in the year 2003. The number of ICDs per million of inhabitants in Italy was 42.1 in the year 2001 (+11.8% with respect to 2000), 69.0 in the year 2002 (+63.9% with respect to 2001), and 93.3 in the year 2003 (+35.2% with respect to 2002). The number of implanting centers increased progressively from 273 in the year 2001 to 304 in the year 2002, and 340 in the year 2003. The median age of patients treated with ICD implantation was 67 years in the years 2001-2002, 68 years in the year 2003. The prevalence of male patients was significantly higher (79.3% in 2001, 82.3% in 2002, and 81.4% in 2003). The main indication was syncope (25.5, 29.3, and 32.9% in the years 2001, 2002, and 2003, respectively), followed by palpitations (17.7, 18.5, and 16.4% in the years 2001, 2002, and 2003, respectively), and cardiac arrest (10.0, 13.1, and 16.5% in the years 2001, 2002, and 2003, respectively). The use of ICD in patients considered at risk but without history of sustained ventricular tachycardia had a 3-fold increase during the 3 years, from 6.4% in 2001 to 18.2% in 2003. Ventricular tachycardia was the main arrhythmia in 50.4 to 55.0% of cases, ventricular fibrillation in 13.5 to 18.1%, both in 4.1 to 6.5%. The vast majority of patients presented at the enrolment either a mild or severe reduction in ejection fraction (30 to 50%, < 30%). Amiodarone was administered alone or in combination with antiarrhythmics in 29.7 to 40.0% of patients. Single-chamber ICDs were implanted in the years 2002 and 2003 in 45.7 and 39.2% of patients, dual-chamber ICDs in 34.9 and 32.4%, biventricular ICDs in 19.4 and 28.4%, respectively.

CONCLUSIONS

The ICD implantation rate in Italy increased significantly in the period 2001-2003, similarly to the trend in the other western countries and following the publication of controlled studies in the field of primary and secondary prevention of sudden cardiac death. The Italian ICD Registry showed during the last 3 years an important increase in prophylactic ICD utilization. A sophisticated ICD, including dual-chamber pacing or cardiac resynchronization therapy, was chosen in a high percentage of patients.

摘要

背景

近年来,多项试验证明植入式心脏复律除颤器(ICD)疗法在预防心脏性猝死以及降低特定高危患者群体的总死亡率方面具有疗效。本综述的目的是报告2001 - 2003年意大利ICD注册研究中入组患者的主要流行病学数据和最重要的临床特征。

方法

意大利ICD注册研究——意大利心律失常与心脏起搏协会(AIAC)的官方成员——基于欧洲植入式除颤器表格(EURID)收集了全国85%的ICD植入活动数据。数据在录入时以及年度分析的后续步骤中会进行信息质量和唯一性验证。

结果

根据欧洲和非欧洲国家的总体趋势,意大利近年来植入ICD的数量持续增加:2001年为2400例,2002年为3934例,2003年为5318例。2001年意大利每百万居民中ICD的植入数量为42.1例(相对于2000年增长11.8%),2002年为69.0例(相对于2001年增长63.9%),2003年为93.3例(相对于2002年增长35.2%)。植入中心的数量从2001年的273个逐渐增加到2002年的304个以及2003年的340个。2001 - 2002年接受ICD植入治疗患者的中位年龄为67岁,2003年为68岁。男性患者的比例显著更高(2001年为79.3%,2002年为82.3%,2003年为81.4%)。主要适应证为晕厥(2001年、2002年和2003年分别为25.5%、29.3%和32.9%),其次是心悸(2001年、2002年和2003年分别为17.7%、18.5%和16.4%)以及心脏骤停(2001年、2002年和2003年分别为10.0%、13.1%和16.5%)。在被认为有风险但无持续性室性心动过速病史的患者中,ICD的使用在3年期间增加了3倍,从2001年的6.4%增至2003年的18.2%。室性心动过速是50.4%至55.0%病例中的主要心律失常,室颤为13.5%至18.1%,两者并存为4.1%至6.5%。绝大多数患者在入组时射血分数出现轻度或重度降低(3 * 0%至50%,< 30%)。29.7%至40.0%的患者单独使用胺碘酮或与抗心律失常药物联合使用。2002年和2003年分别有45.7%和39.2%的患者植入单腔ICD,双腔ICD分别为34.9%和32.4%,双心室ICD分别为19.4%和28.4%。

结论

2001 - 2003年期间,意大利的ICD植入率显著增加,与其他西方国家的趋势相似,且是在心脏性猝死一级和二级预防领域的对照研究发表之后。意大利ICD注册研究显示,在过去3年中预防性ICD的使用有重要增加。在高比例患者中选择了复杂的ICD,包括双腔起搏或心脏再同步治疗。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验